

Relationship between Serum Homocysteine and Other Parameters in Overt Diabetic Nephropathy

Sarasadat Moghadasimousavi¹, Nader Nouri-Majalan^{1, 2 *}

1. Department of Internal Medicine, Shaheed Sadoughi University of Medical Sciences and Health Services, Yazd, Iran

2. Yazd Diabetes Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

Received: 16 April 2012 - Accepted: 15 June 2012

ABSTRACT

OBJECTIVE: Level of serum homocysteine is remarkably common among patients with moderate to severe renal failure. We assessed whether serum homocysteine concentrations were correlated with proteinuria in overt diabetic nephropathy.

MATERIALS AND METHODS: A cross-sectional study was carried out on 45 patients (29 males, 16 females) with overt proteinuria. All subjects had type 2 diabetes. Data included age, sex, hypertension, serum creatinine, creatinine clearance, 24-hour urine proteinuria, lipid profiles and serum homocysteine.

RESULTS: The mean of serum homocysteine concentrations was 18 ± 7.7 $\mu\text{mol/L}$ (4.6-42), having 31 (70%) hyperhomocysteinemia. The mean of 24-hour urine proteinuria was 1515 ± 996 mg, for serum creatinine 1.9 ± 0.7 mg, and for creatinine clearance, it was 97 ± 26.6 mL/min. Serum homocysteine had a negative correlation with creatinine clearance ($r=-0.4$, $p=0.007$) and revealed no correlation with 24-hour proteinuria ($p=0.9$).

CONCLUSION: In overt nephropathy in diabetes type 2, patients with higher homocysteine had lower creatinine clearance. However, there was no correlation between homocysteine and overt proteinuria.

KEY WORDS: Homocysteine, Diabetic Nephropathies, Proteinuria.

INTRODUCTION

The increased susceptibility of diabetic patients with nephropathy can be explained by risk factors such as genetic susceptibility (1), increased glomerular filtration rate (2), obesity (3), and glycemic control. Therefore, the identification of new risk factors is important. Previous studies have investigated correlation between homocysteine (Hcy) and diabetic nephropathy. However, selected patients had just microalbuminuria (4, 5), or patients with overt nephropathy have been compared with ones without nephropathy (6).

We focused just on type 2 diabetic patients

with overt proteinuria and investigated correlations between Hcy and other variables in these patients.

MATERIALS AND METHODS

The study population consisted of 45 type 2 diabetes mellitus patients with overt diabetic nephropathy. Overt nephropathy was diagnosed when 24-hour urine proteinuria was more than 300 mg/day. None of these patients received folic acid, and vitamin b12.

Serum concentrations of creatinine, low-density lipoprotein, high-density lipoprotein, triglycerides, uric acid, and C-reactive protein,

*Correspondence: Nader Nouri-Majalan, Department of Internal Medicine, Shaheed Sadoughi University of Medical Sciences and Health Services, Yazd, Iran. Tel: (+98) 9131526380. Email: dr_nori_majalan@yahoo.com

as well as blood hemoglobin concentrations, were measured using standard methods. Blood samples were drawn after a 12-hour fast. Serum Hcy concentrations were measured by enzyme-linked immunosorbent assay (IBL Company, Hamburg, Germany). Hyperhomocysteinemia was defined as a serum Hcy $\geq 15 \mu\text{mol/L}$. Creatinine clearances (CrCl) were calculated with the Cockcroft-Gault formula.

Statistical Analysis

Pearson coefficient was used for correlation analysis. Student *t*-test was used to compare independent samples and continuous variables with normal distribution. Statistical significance was established at $P < .05$. All data were analyzed with SPSS 13.

RESULTS

The mean age of patients was 58 ± 8 (39-79) years. The mean of serum Hcy concentrations was $18 \pm 7.7 \mu\text{mol/L}$ (4.6-42) having 31 (70%) hyperhomocysteinemia. The mean of 24-hour urine proteinuria was $1515 \pm 996 \text{ mg}$, for serum creatinine $1.9 \pm 0.7 \text{ mg}$, and for CrCl $41 \pm 16 \text{ mL/min}$.

There was no significant difference in Hcy level between males and females (19.3 ± 7 vs $17.8 \pm 8.8 \mu\text{mol/L}$, $p > 0.5$).

Table 1 shows the correlation between serum Hcy level and some variables. Serum Hcy was significantly associated with decline in renal function (Fig. 1). Patients with hyperhomocysteinemia had higher serum creatinine, lower CrCl and there was no difference regarding 24-hour proteinuria in comparison with normohomocysteinemia (Table 2).

DISCUSSION

We have demonstrated that patients with higher Hcy had lower renal clearance. Also, patients with hyperhomocysteinemia had higher serum creatinine. The kidney has a major role in the metabolism of Hcy. Therefore, it could explain why renal failure is an important cause of hyperhomocysteinemia in some studies. The Hcy concentrations rise

Table 1- Correlation between Serum Homocysteine Concentration and Other Variables

Variable	r	p
Age(y)	.04	0.3
Systolic BP (mm Hg)	.09	0.5
Diastolic BP (mm Hg)	.16	0.3
FBS (mg/dL)	.3	0.06
Ch (mg/dL)	-.12	0.4
TG (mg/dL)	.2	0.17
Uric acid (mg/dL)	.11	0.45
Serum Cr (mg/dL)	.3	0.03
CrCl (mL/min)	-.4	0.007
24 hours Urine proteinuria (mg)	-.004	0.9

BP, blood pressure; CrCl, creatinine clearance

Table 2- Renal Function and Proteinuria, Relative to Serum Homocysteine Concentration

Parameter	Homocysteine $\geq 15 \mu\text{mol/L}$ (n=31)	Homocysteine $< 15 \mu\text{mol/L}$ (n=14)	P value
Serum Cr (mg/dL)	2.1 ± 0.75	1.6 ± 0.48	0.048
CrCl (mL/min)	36 ± 13.7	52 ± 17.2	0.003
24 hours urine protein (mg)	1670 ± 1100	1970 ± 725	0.5

Cr, creatinine; CrCl, creatinine clearance

with the increase of creatinine especially in chronic renal failure (6, 7). In our study, there was no association between Hcy concentration and overt proteinuria. The previous studies compared Hcy in diabetes with and without micro or macroalbuminuria. Overt nephropathy type 2 diabetic patients had higher Hcy compared with no proteinuria (7-9). Similar findings have also been shown for type 1 diabetes. Wotherspoon et al. (4) have reported mild hyperhomocysteinemia in microalbuminuria diabetic patients compared with normoalbuminuria diabetic patients. We enrolled only patients with overt nephropathy. More than 80% of the patients had renal dysfunction. It seems the CrCl is a main factor that correlates with Hcy. A cohort study showed baseline Hcy cannot predict proteinuria in overt nephropathy after adjustment for serum creatinine. However, Hcy significantly predict proteinuria in patients with no proteinuria (7). Also, Allon et al. (10) showed proteinuria was not significantly associated with Hcy in either the unadjusted or multivariable analysis when serum creatinine is as a marker of renal function. Similar to these findings, we did not




Figure.1- Correlation between Serum Homocysteine and Creatinine Clearance (A) or Serum Creatinine (B)

find any correlation between Hcy and

proteinuria in overt nephropathy.

In our study, there was no significant difference in Hcy between men and women. Some studies have showed that women have lower Hcy levels than men (11, 12). However, this difference even disappears in middle age (13). Because of our patients were on their middle age, this could be the reason for no differences of Hcy regarding different sexes.

In line with the study by Sally et al. (14), we have found no significant correlation between Hcy and systolic or diastolic hypertension.

Agulló-Ortuño et al. (6) observed that Hcy concentrations in type 2 diabetes was positively correlated with TG and Uric acid. However, this correlation was not observed in type 2 diabetic patients. The present study findings support this result.

Finally, in overt nephropathy in diabetes type 2, patients with hyperhomocysteinemia had lower renal clearance. However, there was no correlation between Hcy and overt proteinuria.

ACKNOWLEDGMENTS

The authors wish to thank the nurses of internal medicine ward of Shahid Sadoughi Hospital for their assistance in helping to do this study.

REFERENCES

1. Adler S. Diabetic nephropathy: Linking histology, cell biology, and genetics. *Kidney Int.* 2004; 66(5):2095-106.
2. Rudberg S, Persson B, Dahlquist G. Increased glomerular filtration rate as a predictor of diabetic nephropathy--an 8-year prospective study. *Kidney Int.* 1992; 41(4):822-8.
3. Tapp RJ, Shaw JE, Zimmet PZ, Balkau B, Chadban SJ, Tonkin AM, et al. Albuminuria is evident in the early stages of diabetes onset: results from the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). *American journal of kidney diseases.* 2004; 44(5):792-8.
4. Wotherspoon F, Laight DW, Browne DL, Turner C, Meeking DR, Allard SE, et al. Plasma homocysteine, oxidative stress and endothelial function in patients with Type 1 diabetes mellitus and microalbuminuria. *Diabetic medicine.* 2006; 23(12):1350-6.
5. González-Clemente JM, Deulofeu R, Mitjavila J, Galdon G, Ortega E, Caixàs A, Et al. Plasma homocysteine is not increased in microalbuminuric patients with type 2 diabetes without clinical cardiovascular disease. *Diabetes Care.* 2002; 25(3):632-3.
6. Agulló-Ortuño MT, Albaladejo MD, Parra S, Rodríguez-Manotas M, Fenollar M, Ruiz-Espejo F, et al. Plasmatic homocysteine concentration and its relationship with complications associated to diabetes mellitus. *Clinica chimica Acta.* 2002; 326(1-2):105-12.
7. Looker HC, Fagot-Campagna A, Gunter EW, Pfeiffer CM, Narayan KM, Knowler WC, et al. Homocysteine as a risk factor for nephropathy and retinopathy in Type 2 diabetes. *Diabetologia.* 2003; 46(6):766-72.
8. Buysschaert M, Dramais AS, Wallemacq PE, Hermans MP. Hyperhomocysteinemia in type 2

- diabetes: relationship to macroangiopathy, nephropathy, and insulin resistance. *Diabetes Care*. 2000; 23(12):1816-22.
9. Chiarelli F, Pomilio M, Mohn A, Tumini S, Vanelli M, Morgese G, et al. Homocysteine levels during fasting and after methionine loading in adolescents with diabetic retinopathy and nephropathy. *The Journal of pediatrics*. 2000; 137(3):386-92.
 10. Friedman AN, Hunsicker LG, Selhub J, Bostom AG; Collaborative Study Group. Proteinuria as a predictor of total plasma homocysteine levels in type 2 diabetic nephropathy. *Diabetes Care*. 2002; 25(11):2037-41.
 11. Bates CJ, Mansoor MA, van der Pols J, Prentice A, Cole TJ, Finch S. Plasma total homocysteine in a representative sample of 972 British men and women aged 65 and over. *European journal of clinical nutrition*. 1997; 51(10):691-7.
 12. Jacobsen DW, Gatautis VJ, Green R, Robinson K, Savon SR, Secic M, et al. Rapid HPLC determination of total homocysteine and other thiols in serum and plasma: sex differences and correlation with cobalamin and folate concentrations in healthy subjects. *Clinical chemistry*. 1994; 40(6):873-81.
 13. Jacques PF, Rosenberg IH, Rogers G, Selhub J, Bowman BA, Gunter EW, et al. Serum total homocysteine concentrations in adolescent and adult Americans: results from the third National Health and Nutrition Examination Survey. *The American Journal of Clinical Nutrition*. 1999; 69(3):482-9.
 14. Stabler SP, Estacio R, Jeffers BW, Cohen JA, Allen RH, Schrier RW. Total homocysteine is associated with nephropathy in non-insulin-dependent diabetes mellitus. *Metabolism*. 1999; 48(9):1096-101.